Compare Dollar Tree, Inc. (DLTR) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs Merck & Co., Inc. — how do they compare? Dollar Tree, Inc. trades at $118.58 (market cap $22.26B), while Merck & Co., Inc. trades at $141.98 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 15.8× Dollar Tree, Inc.'s market cap, and Merck & Co., Inc. pays a 2.39% dividend while Dollar Tree, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dollar Tree, Inc. for 58 Days and Merck & Co., Inc. for 98 Days on average.
| DLTR | MRK | |
|---|---|---|
Market Cap | $22.26B | $351.28B |
Volume | 2,317,428 | 7,969,665 |
Sector | Consumer Staples | Health |
52-Week High | $141.21 | $156.43 |
52-Week Low | $86.80 | $82.49 |
Typical Hold Time | 58 Days | 98 Days |
Enterprise Value | $28.87B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $116.3, up slightly by 0.09% on the day, with a bullish technical signal and strong analyst support. The stock shows robust earnings beats in recent quarters, with Q2 2026 EPS of $2.70 significantly exceeding the $1.15 estimate. Revenue for 2025 was $17.58 billion, though net income was negative due to a large tax expense, while 2026 projections indicate a return to profitability. Strategic initiatives like store expansions and a multi-price strategy are driving growth, supported by positive institutional buying activity.
The outlook for DLTR is positive, with a consensus price target of $139.33 offering ~20% upside. Key opportunities include continued earnings momentum and market share gains, but risks involve margin pressures from tariffs and rising costs. Investors should weigh the strong ROE of 45.87% against volatility in net income and competitive discount retail dynamics.
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
